Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.49 |
| ▸ | RAB9A | P51151 | 7/20 | 0.49 |
| ▸ | NPC1 | O15118 | 5/20 | 0.49 |
| ▸ | HTT | P42858 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.45 |
| ▸ | MEN1 | O00255 | 5/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 1/20 | 0.43 |
| ▸ | ROS1 | P08922 | 1/20 | 0.43 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | MITF | O75030 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.40 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12120816 | 0.81 | SYK (0.48) | MAPTRAB9ANPC1HTTKMT2A | |
| SCHEMBL28303894 | 0.79 | RAB9A (0.52) | MAPTRAB9ANPC1HTTKMT2A | |
| SCHEMBL8909090 | 0.75 | MEN1 (0.45) | MAPTRAB9ANPC1HTTKMT2A | |
| SCHEMBL21729933 | 0.75 | TDP1 (0.79) | MAPTRAB9ANPC1HTTKMT2A | |
| SCHEMBL21729918 | 0.74 | MAPT (0.53) | MAPTRAB9ANPC1HTTKMT2A | |
| SCHEMBL12120819 | 0.74 | SYK (0.53) | RAB9ANPC1KMT2AMEN1EGFR | |
| SCHEMBL21729899 | 0.73 | MAPT (0.48) | MAPTRAB9ANPC1HTTKMT2A | |
| SCHEMBL4150750 | 0.72 | KIF11 (0.49) | MAPTALDH1A1 | |
| SCHEMBL28106110 | 0.71 | SCN9A (0.57) | MAPTRAB9ANPC1KMT2AMEN1 | |
| SCHEMBL28303834 | 0.71 | EGFR (0.46) | MAPTRAB9ANPC1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220062281-A1 | INHIBITORS TO TARGET HIV-1 NEF-CD80/CD86 INTERACTIONS FOR THERAPEUTIC INTERVENTION | NAT CENTRE FOR BIOLOGICAL SCIENCES TIFR (IN) | 2022-03-03 | — | — | US | disclosed |
| WO-2020035880-A1 | INHIBITORS TO TARGET HIV-1 NEF-CD80/CD86 INTERACTIONS FOR THERAPEUTIC INTERVENTION | NATIONAL CENTRE FOR BIOLOGICAL SCIENCES-TIFR (IN) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220062281-A1 | INHIBITORS TO TARGET HIV-1 NEF-CD80/CD86 INTERACTIONS FOR THERAPEUTIC INTERVENTION | CD4, CD14, CD69 | MAPT 298/4885RAB9A 997/4885NPC1 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.